These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1756 related articles for article (PubMed ID: 18768342)
1. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Park SK; Kim JH; Kang H; Cho JS; Smego RA Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342 [TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154 [TBL] [Abstract][Full Text] [Related]
3. Surgical treatment for multidrug-resistant and extensive drug-resistant tuberculosis. Kang MW; Kim HK; Choi YS; Kim K; Shim YM; Koh WJ; Kim J Ann Thorac Surg; 2010 May; 89(5):1597-602. PubMed ID: 20417785 [TBL] [Abstract][Full Text] [Related]
5. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [TBL] [Abstract][Full Text] [Related]
6. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Park SK; Kim CT; Song SD Int J Tuberc Lung Dis; 1998 Nov; 2(11):877-84. PubMed ID: 9848607 [TBL] [Abstract][Full Text] [Related]
7. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study]. Yoshiyama T; Ogata H; Ito K; Aono A; Wada M Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318 [TBL] [Abstract][Full Text] [Related]
8. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance. Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897 [TBL] [Abstract][Full Text] [Related]
9. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823 [TBL] [Abstract][Full Text] [Related]
10. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Nolan CM; Goldberg SV Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140 [TBL] [Abstract][Full Text] [Related]
12. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan. Lai CC; Tan CK; Huang YT; Chou CH; Hung CC; Yang PC; Luh KT; Hsueh PR Clin Infect Dis; 2008 Oct; 47(7):e57-63. PubMed ID: 18715157 [TBL] [Abstract][Full Text] [Related]
13. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India. Ramachandran R; Nalini S; Chandrasekar V; Dave PV; Sanghvi AS; Wares F; Paramasivan CN; Narayanan PR; Sahu S; Parmar M; Chadha S; Dewan P; Chauhan LS Int J Tuberc Lung Dis; 2009 Sep; 13(9):1154-60. PubMed ID: 19723407 [TBL] [Abstract][Full Text] [Related]
14. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis]. Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883 [TBL] [Abstract][Full Text] [Related]
15. [Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study]. Li L; Zheng SH; Chu NH; Xie YG; Yang YZ; Li Q; Wang XM; Yan XL; Tan WG; Miao ZP; Duanmu HJ Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3387-91. PubMed ID: 19159566 [TBL] [Abstract][Full Text] [Related]
17. Impact of extensively drug-resistant tuberculosis on treatment outcome of multidrug-resistant tuberculosis patients with standardized regimen: report from Iran. Tabarsi P; Chitsaz E; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Amiri M; Mansouri D; Masjedi MR; Velayati AA; Caminero JA Microb Drug Resist; 2010 Mar; 16(1):81-6. PubMed ID: 20192820 [TBL] [Abstract][Full Text] [Related]
18. [Frequency of MDR-TB/XDR-TB strains isolated from chronic pulmonary tuberculosis patients in Japan]. Kazumi Y; Itagaki N; Ohmori M; Wada M; Hoshino H; Mitarai S; Sugawara I; Ishikawa N; Mori T Kekkaku; 2007 Dec; 82(12):891-6. PubMed ID: 18188977 [TBL] [Abstract][Full Text] [Related]
19. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Prasad R; Verma SK; Sahai S; Kumar S; Jain A Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]